ClinicalTrials.gg
CompletedNCT03205163Updated Apr 19, 2022Results posted

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

A Phase 1/2 interventional study of Advate (Low Dose) and Advate (High Dose) in Hemophilia A, sponsored by Bioverativ, a Sanofi company. Completed at 10 sites in 2 countries. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-19.

Sponsored by Bioverativ, a Sanofi company (part of Sanofi) · Phase 1/2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing efanesoctocog alfa in Hemophilia A — 1 open to participants now, 5 under way, 2 of them phase 3. efanesoctocog alfa · Hemophilia A.

Enrollment
10th of 11
16 · median 74
Started
2017
the only one that year
Phase 1/2
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
4 of 11
Bioverativ, a Sanofi company

Among the 11 studies testing efanesoctocog alfa in Hemophilia A, this one is the 10th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 1st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 11 studies testing efanesoctocog alfa in Hemophilia A is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About efanesoctocog alfa

efanesoctocog alfa: first FDA approval 2023 (ALTUVIIIO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing efanesoctocog alfa in Hemophilia A, or all of them as a file.
02

Study summary

The primary purpose was to assess the safety and tolerability of a single intravenous (IV) administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia A.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability of the participant, or his legally authorized representative (e.g., parent or legal guardian) if applicable in accordance with local regulations, to understand the purpose and risks of the study and provide signed and dated /assent and authorization to use confidential health information in accordance with national and local participant privacy regulations.
  • Severe hemophilia A, defined as less than (\<) 1 international units per deciliter (IU/dL) (\<1 percent [%]) endogenous FVIII at screening as determined by the one-stage clotting assay from the central laboratory. If the initial screening result was greater than or equal to (>=) 1%, then a repeat endogenous FVIII activity level was performed using the one stage clotting assay from the central laboratory. If the repeated result was \< 1 IU/dL (\<1%), then the participant met this inclusion requirement.
  • Previous treatment for hemophilia A, defined as at least 150 documented prior exposure days to any recombinant and/or plasma-derived FVIII and/or cryoprecipitate products at Day 1. Fresh frozen plasma treatment must not be considered in the count for documented exposure days.
  • count >=100,000 cells/ microliter (mcL) at screening (test performed by the central laboratory and reviewed prior to the Day 1 Advate dose).
  • A participant known to be (HIV) antibody positive, either previously documented or identified from screening assessments, must have the following results prior to Day 1 Advate dose: cluster of differentiation 4 (CD4) lymphocyte count greater than (>) 200 cells/millimeter (mm)\^3; viral load of \<400 copies/mL.

Exclusion criteria

Exclusion Criteria:

Medical History:

  • Any concurrent major disease that, in the opinion of the Investigator, made the participant unsuitable for enrollment.
  • Serious active bacterial or viral infection (other than chronic hepatitis or ) present within 30 days of screening.
  • Other known coagulation disorder(s) in addition to hemophilia A.
  • History of or anaphylaxis associated with any FVIII product.
  • Known or suspected allergy to mice, hamsters, or any ingredient in Advate.
  • History of a positive inhibitor test or clinical signs of decreased response to FVIII administrations. Family history of inhibitors not excluded the participant.

Medications and Procedures:

  • Current enrollment or participation within 30 days prior to screening in any other study.

Other:

  • Inability to comply with study requirements as assessed by the Investigator.
  • Other unspecified reasons that, in the opinion of the Investigator or Sponsor, made the participant unsuitable for enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg

    Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.

    Biological: Advate (Low Dose) · Biological: BIVV001 (Low Dose)

  • Experimental
    High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg

    Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.

    Biological: Advate (High Dose) · Biological: BIVV001 (High Dose)

Interventions

  • Participants received a single IV low dose of Advate 25 IU/kg.

  • Participants received a single IV high dose of Advate 65 IU/kg.

  • Participants received single IV low dose of BIVV001 25 IU/kg.

  • Participants received single IV high dose of BIVV001 65 IU/kg.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment Period

    AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the single dose of Advate but before the single dose of BIVV001. Serious AE (SAE) was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.

    Time frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg

  2. Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During BIVV001 Treatment Period

    AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the study treatment (BIVV001) and within 28 days after BIVV001 administration. SAE was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.

    Time frame: Up to 28 days after BIVV001 administration

  3. Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment Period

    Number of Participants with Clinically Significant Abnormalities in Laboratory tests (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.

    Time frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg

  4. Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment Period

    Number of participants with clinically significant abnormalities (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.

    Time frame: Up to 28 days after BIVV001 administration

  5. Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay

    Development of an inhibitor was defined as a neutralizing antibody value of greater than or equal to (\>=) 0.6 Bethesda units per milliliter (BU/mL) identified and confirmed by a second test on an independent sample, collected within 2 to 4 weeks of the first positive sample, with both tests performed by the central laboratory using Nijmegen-modified Bethesda assay.

    Time frame: Up to 28 days after BIVV001 administration

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (Low Dose Comparison)

    Cmax of Advate and BIVV001 at low dose was assessed and compared based on One-stage activated partial thromboplastin time (aPTT)-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  2. PK: Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (High Dose Comparison)

    Cmax of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

  3. PK: Half-Life (t1/2) for Advate and BIVV001 (Low Dose Comparison)

    Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  4. PK: Half-Life for Advate and BIVV001 (High Dose Comparison)

    Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

  5. PK: Total Body Clearance (CL) for Advate and BIVV001 (Low Dose Comparison)

    Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  6. PK: Total Body Clearance (CL) for Advate and BIVV001 (High Dose Comparison)

    Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

  7. PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (Low Dose Comparison)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  8. PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (High Dose Comparison)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

  9. PK: Area Under the Concentration Time Curve (AUC) From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (Low Dose Comparison)

    AUCinfinity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  10. PK: Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (High Dose Comparison)

    AUCinfinity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

  11. PK: Mean Residence Time (MRT) for Advate and BIVV001 (Low Dose Comparison)

    The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  12. PK: Mean Residence Time (MRT) for Advate and BIVV001 (High Dose Comparison)

    The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

  13. PK: Incremental Recovery (IR) for Advate and BIVV001 (Low Dose Comparison)

    Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  14. PK: Incremental Recovery (IR) for Advate and BIVV001 (High Dose Comparison)

    Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

  15. PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (Low Dose Comparison)

    Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours

  16. PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (High Dose Comparison)

    Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

    Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours

07

Results

Posted Dec 2, 2019

Participant flow

The study was conducted in Japan and United States between 28 August 2017 to 12 November 2018.

ATP (LDC: 3 Days; HDC: 4 Days)
Participant flow — ATP (LDC: 3 Days; HDC: 4 Days)
MilestoneLow Dose Cohort (LDC): Advate 25 IU/kg Then BIVV001 25 IU/kgHigh Dose Cohort (HDC): Advate 65 IU/kg Then BIVV001 65 IU/kg
Started79
Safety population79
Completed69
Not completed10
Withdrew: Sponsor decision10
BTP (LDC: 28 Days; HDC: 28 Days)
Participant flow — BTP (LDC: 28 Days; HDC: 28 Days)
MilestoneLow Dose Cohort (LDC): Advate 25 IU/kg Then BIVV001 25 IU/kgHigh Dose Cohort (HDC): Advate 65 IU/kg Then BIVV001 65 IU/kg
Started69
Safety population69
Completed69
Not completed00

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment Period

AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the single dose of Advate but before the single dose of BIVV001. Serious AE (SAE) was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.

Time frame:
Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment Period
ParticipantsAdvate 25 IU/kgAdvate 65 IU/kg
TEAE21
TESAE10
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During BIVV001 Treatment Period

AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the study treatment (BIVV001) and within 28 days after BIVV001 administration. SAE was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.

Time frame:
Up to 28 days after BIVV001 administration
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During BIVV001 Treatment Period
ParticipantsBIVV001 25 IU/kgBIVV001 65 IU/kg
TEAE36
TESAE10
PrimaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment Period

Number of Participants with Clinically Significant Abnormalities in Laboratory tests (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.

Time frame:
Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment Period
ParticipantsAdvate 25 IU/kgAdvate 65 IU/kg
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment Period00
PrimaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment Period

Number of participants with clinically significant abnormalities (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.

Time frame:
Up to 28 days after BIVV001 administration
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment Period
ParticipantsBIVV001 25 IU/kgBIVV001 65 IU/kg
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment Period00
PrimaryPercentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay

Development of an inhibitor was defined as a neutralizing antibody value of greater than or equal to (\>=) 0.6 Bethesda units per milliliter (BU/mL) identified and confirmed by a second test on an independent sample, collected within 2 to 4 weeks of the first positive sample, with both tests performed by the central laboratory using Nijmegen-modified Bethesda assay.

Time frame:
Up to 28 days after BIVV001 administration
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
percentage of participantsLow Dose Cohort (LDC): Advate 25 IU/kg Then BIVV001 25 IU/kgHigh Dose Cohort (HDC): Advate 65 IU/kg Then BIVV001 65 IU/kg
Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay00
SecondaryPharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (Low Dose Comparison)

Cmax of Advate and BIVV001 at low dose was assessed and compared based on One-stage activated partial thromboplastin time (aPTT)-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · International unit/deciliter (IU/dL)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (Low Dose Comparison)
International unit/deciliter (IU/dL)Advate 25 IU/kgBIVV001 25 IU/kg
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (Low Dose Comparison)51.8 (43.3 to 61.9)70.1 (49.7 to 98.9)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = 0.032 · Gmr: 1.35 · 95% CI 1.04 to 1.77
SecondaryPK: Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (High Dose Comparison)

Cmax of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · IU/dL
PK: Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (High Dose Comparison)
IU/dLAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (High Dose Comparison)138 (117 to 162)161 (142 to 183)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 1.17 · 95% CI 1.09 to 1.25
SecondaryPK: Half-Life (t1/2) for Advate and BIVV001 (Low Dose Comparison)

Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · hours
PK: Half-Life (t1/2) for Advate and BIVV001 (Low Dose Comparison)
hoursAdvate 25 IU/kgBIVV001 25 IU/kg
PK: Half-Life (t1/2) for Advate and BIVV001 (Low Dose Comparison)9.12 (6.24 to 13.33)37.61 (33.28 to 42.50)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = <0.001 · Gmr: 4.13 · 95% CI 2.94 to 5.79
SecondaryPK: Half-Life for Advate and BIVV001 (High Dose Comparison)

Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · hours
PK: Half-Life for Advate and BIVV001 (High Dose Comparison)
hoursAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Half-Life for Advate and BIVV001 (High Dose Comparison)13.15 (10.89 to 15.87)42.54 (39.72 to 45.56)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 3.24 · 95% CI 2.76 to 3.79
SecondaryPK: Total Body Clearance (CL) for Advate and BIVV001 (Low Dose Comparison)

Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · milliliter/hour/kilogram (mL/hr/kg)
PK: Total Body Clearance (CL) for Advate and BIVV001 (Low Dose Comparison)
milliliter/hour/kilogram (mL/hr/kg)Advate 25 IU/kgBIVV001 25 IU/kg
PK: Total Body Clearance (CL) for Advate and BIVV001 (Low Dose Comparison)3.91 (3.05 to 5.02)0.558 (0.411 to 0.757)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = <0.001 · Gmr: 0.143 · 95% CI 0.118 to 0.172
SecondaryPK: Total Body Clearance (CL) for Advate and BIVV001 (High Dose Comparison)

Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · mL/hr/kg
PK: Total Body Clearance (CL) for Advate and BIVV001 (High Dose Comparison)
mL/hr/kgAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Total Body Clearance (CL) for Advate and BIVV001 (High Dose Comparison)3.31 (2.81 to 3.88)0.505 (0.436 to 0.586)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 0.153 · 95% CI 0.138 to 0.170
SecondaryPK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (Low Dose Comparison)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · milliliter/kilogram (mL/kg)
PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (Low Dose Comparison)
milliliter/kilogram (mL/kg)Advate 25 IU/kgBIVV001 25 IU/kg
PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (Low Dose Comparison)55.9 (51.2 to 61.0)34.8 (27.3 to 44.3)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = 0.003 · Gmr: 0.622 · 95% CI 0.492 to 0.786
SecondaryPK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (High Dose Comparison)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · mL/kg
PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (High Dose Comparison)
mL/kgAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (High Dose Comparison)58.3 (49.8 to 68.2)35.0 (29.7 to 41.1)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 0.599 · 95% CI 0.525 to 0.684
SecondaryPK: Area Under the Concentration Time Curve (AUC) From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (Low Dose Comparison)

AUCinfinity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · hour*international unit/deciliter
PK: Area Under the Concentration Time Curve (AUC) From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (Low Dose Comparison)
hour*international unit/deciliterAdvate 25 IU/kgBIVV001 25 IU/kg
PK: Area Under the Concentration Time Curve (AUC) From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (Low Dose Comparison)638 (495 to 822)4470 (3280 to 6080)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = <0.001 · Gmr: 7.00 · 95% CI 5.78 to 8.48
SecondaryPK: Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (High Dose Comparison)

AUCinfinity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · hour*international unit/deciliter
PK: Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (High Dose Comparison)
hour*international unit/deciliterAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (High Dose Comparison)1960 (1670 to 2310)12800 (11100 to 14900)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 6.54 · 95% CI 5.89 to 7.27
SecondaryPK: Mean Residence Time (MRT) for Advate and BIVV001 (Low Dose Comparison)

The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · hours
PK: Mean Residence Time (MRT) for Advate and BIVV001 (Low Dose Comparison)
hoursAdvate 25 IU/kgBIVV001 25 IU/kg
PK: Mean Residence Time (MRT) for Advate and BIVV001 (Low Dose Comparison)12.54 (9.82 to 16.01)56.93 (49.19 to 65.89)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = <0.001 · Gmr: 4.54 · 95% CI 3.64 to 5.66
SecondaryPK: Mean Residence Time (MRT) for Advate and BIVV001 (High Dose Comparison)

The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · hours
PK: Mean Residence Time (MRT) for Advate and BIVV001 (High Dose Comparison)
hoursAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Mean Residence Time (MRT) for Advate and BIVV001 (High Dose Comparison)15.66 (14.06 to 17.45)67.66 (62.59 to 73.14)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 4.32 · 95% CI 3.96 to 4.72
SecondaryPK: Incremental Recovery (IR) for Advate and BIVV001 (Low Dose Comparison)

Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · IU/dL per IU/kg
PK: Incremental Recovery (IR) for Advate and BIVV001 (Low Dose Comparison)
IU/dL per IU/kgAdvate 25 IU/kgBIVV001 25 IU/kg
PK: Incremental Recovery (IR) for Advate and BIVV001 (Low Dose Comparison)2.0 (1.60 to 2.50)2.72 (1.95 to 3.80)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = 0.063 · Gmr: 1.36 · 95% CI 0.978 to 1.89
SecondaryPK: Incremental Recovery (IR) for Advate and BIVV001 (High Dose Comparison)

Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · IU/dL per IU/kg
PK: Incremental Recovery (IR) for Advate and BIVV001 (High Dose Comparison)
IU/dL per IU/kgAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Incremental Recovery (IR) for Advate and BIVV001 (High Dose Comparison)2.11 (1.79 to 2.49)2.48 (2.18 to 2.82)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 1.18 · 95% CI 1.10 to 1.26
SecondaryPK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (Low Dose Comparison)

Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
Reported as:
Geometric mean · hours
PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (Low Dose Comparison)
hoursAdvate 25 IU/kgBIVV001 25 IU/kg
PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (Low Dose Comparison)56.97 (49.25 to 65.89)260.53 (222.34 to 305.30)
Statistical analysis
  • Advate 25 IU/kg vs BIVV001 25 IU/kg · ANOVA · p = <0.001 · Gmr: 4.57 · 95% CI 4.00 to 5.23
SecondaryPK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (High Dose Comparison)

Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.

Time frame:
For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
Reported as:
Geometric mean · hours
PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (High Dose Comparison)
hoursAdvate 65 IU/kgBIVV001 65 IU/kg
PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (High Dose Comparison)78.48 (70.88 to 86.89)350.34 (326.61 to 375.81)
Statistical analysis
  • Advate 65 IU/kg vs BIVV001 65 IU/kg · ANOVA · p = <0.001 · Gmr: 4.46 · 95% CI 4.16 to 4.79

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to end of the study (28 days after BIVV001 administration) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Advate Dose Level: 25 IU/kg0/7 (0%)1/7 (14.3%)1/7 (14.3%)
Advate Dose Level: 65 IU/kg0/9 (0%)0/9 (0%)1/9 (11.1%)
BIVV001 Dose Level: 25 IU/kg0/6 (0%)1/6 (16.7%)3/6 (50%)
BIVV001 Dose Level: 65 IU/kg0/9 (0%)0/9 (0%)6/9 (66.7%)
Most frequent serious events
Most frequent serious events
EventAdvate Dose Level: 25 IU/kgAdvate Dose Level: 65 IU/kgBIVV001 Dose Level: 25 IU/kgBIVV001 Dose Level: 65 IU/kg
Small intestinal obstructionGastrointestinal disorders0/70/91/60/9
ContusionInjury, poisoning and procedural complications1/70/90/60/9
Road traffic accidentInjury, poisoning and procedural complications1/70/90/60/9
HaemarthrosisMusculoskeletal and connective tissue disorders1/70/90/60/9
TendonitisMusculoskeletal and connective tissue disorders1/70/90/60/9
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAdvate Dose Level: 25 IU/kgAdvate Dose Level: 65 IU/kgBIVV001 Dose Level: 25 IU/kgBIVV001 Dose Level: 65 IU/kg
DiarrhoeaGastrointestinal disorders0/70/91/60/9
Gingival painGastrointestinal disorders0/70/91/60/9
Thrombin-antithrombin iii complex increasedInvestigations1/71/91/61/9
Pain in jawMusculoskeletal and connective tissue disorders0/70/91/60/9
HeadacheNervous system disorders0/70/91/61/9
Coagulation test abnormalInvestigations1/70/90/60/9
PalpitationsCardiac disorders0/70/90/61/9
NasopharyngitisInfections and infestations0/70/90/61/9
Viral upper respiratory tract infectionInfections and infestations0/70/90/61/9
Joint injuryInjury, poisoning and procedural complications0/70/90/61/9

Baseline characteristics

Baseline population included all enrolled participants.

Age, Continuous
Age, Continuous(years)LDC: Advate 25 IU/kg Then BIVV001 25 IU/kgHDC: Advate 65 IU/kg Then BIVV001 65 IU/kgTotal
Mean33.0 ± 13.8144.0 ± 11.6539.2 ± 13.43
Sex: Female, Male
Sex: Female, Male(Participants)LDC: Advate 25 IU/kg Then BIVV001 25 IU/kgHDC: Advate 65 IU/kg Then BIVV001 65 IU/kgTotal
Female000
Male7916
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LDC: Advate 25 IU/kg Then BIVV001 25 IU/kgHDC: Advate 65 IU/kg Then BIVV001 65 IU/kgTotal
American Indian or Alaska Native011
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6713
More than one race000
Unknown or Not Reported000
08

Study locations

10 sites
  • University of California Los Angeles Medical Center
    Los Angeles, California 90007, United States
  • Indiana Hemophilia and Thrombosis Center
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Michigan State University
    East Lansing, Michigan 48823, United States
  • Mississippi Center for Advanced Medicine
    Madison, Mississippi 39110, United States
  • Hemophilia Center of Western PA
    Pittsburgh, Pennsylvania 15213, United States
  • University of Washington
    Seattle, Washington 98104, United States
  • Nara Medical University Hospital
    Kashihara-Shi, Nara-Ken 634-8521, Japan
  • Tokyo Medical University Hospital
    Shinjuku-Ku, Tokyo-To 160-0023, Japan
  • Ogikubo Hospital
    Tokyo, Tokyo-To 167-8515, Japan
09

References and documents

Publications

  • Konkle BA, Shapiro AD, Quon DV, Staber JM, Kulkarni R, Ragni MV, Chhabra ES, Poloskey S, Rice K, Katragadda S, Fruebis J, Benson CC. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med. 2020 Sep 10;383(11):1018-1027. doi: 10.1056/NEJMoa2002699. PubMed 32905674 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Nov 2018, 14 months.

Results were first posted in Dec 2019, 1 year after primary completion.

Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2017
First posted
Jul 2, 2017
StartActual
Aug 28, 2017
Primary completionActual
Nov 12, 2018
CompletionActual
Nov 12, 2018
Results first posted
Dec 2, 2019
Last update
Apr 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03205163
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Aug 28, 2017
Primary completion
Nov 12, 2018
Completion
Nov 12, 2018
Results posted
Dec 2, 2019
Last update
Apr 19, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efanesoctocog alfa

Start the discussion